Treatment effects of monosialotetrahexosylganglioside on severe traumatic brain injury in adults.

OBJECTIVE

To determine the effects of monosialotetrahexosylganglioside (GM-1) on the curative effect on severe traumatic brain injury (TBI) in adults and assess the changes of serum inflammatory factors.

METHODS

Retrospective analysis was used in this study. A total of 130 adult patients with severe TBI treated in our hospital from April 2019 to July 2021 were enrolled. Among them, 63 patients treated with conventional therapy were grouped as the control group (Con group), and 67 patients given GM-1 based on conventional therapy were grouped as the observation group (Obs group). The therapeutic efficacy and incidence of adverse reactions were compared between the two groups. The Mini-Mental State Examination (MMSE), Glasgow coma scale (GCS), serum neuron specific enolase (NSE), and Barthel index were adopted for evaluating the two groups after treatment, and the two groups were compared in inflammatory response and stress response.

RESULTS

After treatment, the Obs group showed a significantly higher total effective rate and a significantly lower total incidence of complications than the Con group (P<0.05), and also had significantly higher MMSE score, GCS score and Barthel index than the Con group (P<0.05). After treatment, the NSE level in the Obs group was significantly lower than that in the Con group. Additionally, after treatment, the Obs group showed significantly lower levels of IL-6, IL-8 and TNF-α, a significantly higher SOD level, and a significantly lower MDA level than the Con group (P<0.05).

CONCLUSION

For patients with severe TBI, adjuvant therapy with GM-1 can significantly raise the therapeutic effect and improve the nerve function and inflammatory reaction, which is worthy of clinical application.